Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sales Rep Promotions in June Double against May: Intage
August 7, 2020
- GSK, KM Biologics in Adjuvant Tech Transfer Talks for COVID-19 Vaccines
August 7, 2020
- Torii Gets Japan Option Rights to Verrica’s Warts Drug
August 6, 2020
- MSD Japan Chief Wants Talks with Govt, Re-Pricing Rules Revisited to Help Innovation Thrive
August 6, 2020
- SymBio to Tap Into Global Development of Brincidofovir IV for Post-HSTC Adenovirus Infection
August 6, 2020
- Takara Bio to End License Deal for Oncolytic Viral Immunotherapy with Chinese Firm
August 6, 2020
- Sumitomo Dainippon, Save Medical Link Up on Diabetes App; Approval Eyed in FY2022
August 6, 2020
- LTL Pharma to Take Over Sanofi’s Dellegra in Japan
August 5, 2020
- Astellas’ Q1 Sales Falter 8% on Deal Terminations, COVID-19
August 5, 2020
- Celltrion Poised to Roll Out 20 Biosimilars in Japan over Next 10 Years
August 5, 2020
- Povidone-Iodine Gargle Meds Fly Off Pharmacy Shelves after Osaka COVID-19 Data
August 5, 2020
- First Patient Enrolled in Clinical Trial to Test 3 Drugs for COVID-19: AbbVie, Amgen, Takeda
August 5, 2020
- Mitsubishi Tanabe’s Sales Drop 6.5% in Q1, 5 Billion Yen Loss on Price Cuts
August 5, 2020
- PeptiDream, RayzeBio Tie Up on Peptide-Radiotherapeutics
August 5, 2020
- 4 More Products Recalled over Flawed Testing at Kyowa CritiCare
August 4, 2020
- Kyorin Out-Licenses Hearing Loss Med to Otonomy
August 4, 2020
- Paper Maker Oji Ventures into Pharma Biz with Wood-Derived Drugs, Eyes Clinical Trial by 2023
August 4, 2020
- Eisai Shakes Off Price Cut, Coronavirus Blow with Lenvima Growth in Q1
August 4, 2020
- 2 Astellas Sales Reps Infected with Novel Coronavirus
August 4, 2020
- Daiichi Sankyo to Curb Shipments for Herceptin Biosimilar on Surging Demand
August 4, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…